Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome

Fertil Steril. 2011 Aug;96(2):501-504.e2. doi: 10.1016/j.fertnstert.2011.05.091. Epub 2011 Jul 5.

Abstract

In this randomized, double-blind, placebo-controlled study, 19 overweight women with polycystic ovary syndrome were randomized to a 3-month course of either metformin plus combined hormonal oral contraceptive (OC) (n = 9) or OC plus matched placebo (n = 10). After 3 months, both treatments had similar effects on androgen levels, lipid profile, insulin sensitivity, and serum inflammatory markers, but flow-mediated dilatation increased by 69.0% in the metformin plus OC group while it remained unchanged in the OC group. CLINICAL TRIAL REGISTRATION NO: NCT00682890.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Analysis of Variance
  • Biomarkers / blood
  • Blood Glucose / drug effects
  • Contraceptives, Oral, Combined / administration & dosage*
  • Contraceptives, Oral, Hormonal / administration & dosage*
  • Double-Blind Method
  • Drug Combinations
  • Drug Therapy, Combination
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / physiopathology
  • Ethinyl Estradiol / administration & dosage*
  • Female
  • Gonadal Steroid Hormones / blood
  • Humans
  • Hypoglycemic Agents / administration & dosage*
  • Inflammation Mediators / blood
  • Insulin / blood
  • Insulin Resistance
  • Lipids / blood
  • Metformin / administration & dosage*
  • Norgestrel / administration & dosage
  • Norgestrel / analogs & derivatives*
  • Obesity / blood
  • Obesity / complications*
  • Obesity / physiopathology
  • Overweight / blood
  • Overweight / complications*
  • Overweight / physiopathology
  • Placebo Effect
  • Polycystic Ovary Syndrome / blood
  • Polycystic Ovary Syndrome / complications
  • Polycystic Ovary Syndrome / drug therapy*
  • Polycystic Ovary Syndrome / physiopathology
  • Time Factors
  • Treatment Outcome
  • Vasodilation / drug effects
  • Virginia

Substances

  • Biomarkers
  • Blood Glucose
  • Contraceptives, Oral, Combined
  • Contraceptives, Oral, Hormonal
  • Drug Combinations
  • Gonadal Steroid Hormones
  • Hypoglycemic Agents
  • Inflammation Mediators
  • Insulin
  • Lipids
  • norgestimate, ethinyl estradiol drug combination
  • Norgestrel
  • Ethinyl Estradiol
  • Metformin

Associated data

  • ClinicalTrials.gov/NCT00682890